ArticleInternational journal of surgery (London, England)2025
Ablation versus sublobar resection for stage IA non-small cell lung cancer: a multicenter retrospective cohort study using a deep learning model in the ablation group.
Article in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImage-guided thermal ablation (IGTA) has increasingly been used for stage IA non-small cell lung cancer (NSCLC), yet long-term outcomes comparing IGTA with sublobar resection (SLR) without surgical contraindications remain unclear. Identifying patients who may benefit from ablation is also technically challenging. MATERIALS AND
methodsA total of 2,145 patients treated with IGTA or SLR from 2012 to 2023 were analyzed. Propensity score matching was performed. Progression-free survival (PFS) and cancer-specific survival (CSS) rates were estimated using the Kaplan-Meier method. A deep learning model based on pre-treatment computed tomography images was developed to predict disease-free survival after IGTA and identify patients most appropriate for ablation.
resultsAfter matching, the median follow-up was 39.3 months for the SLR group and 46.7 months for the IGTA group. No significant differences were observed in PFS (hazard ratio [HR], 2.02; 95% confidence interval [CI], 0.83-4.89; P = 0.120) or CSS (HR, 3.09; 95% CI, 0.87-11.04; P = 0.082). The area under the curve (AUC) of the Vision Transformer (ViT) model was 0.826 and 0.814 for the training and external validation cohorts, respectively. Higher ViT scores predicted worse survival (HR, 8.61; P < 0.001). The Multimodal XGBoost model further improved the performance.
conclusionIn this study, long-term outcomes after IGTA were not significantly different from those after SLR in patients with stage IA NSCLC. The ViT model accurately predicted outcomes after ablation. These results indicate that ablation may be a feasible alternative to conventional surgery in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.